NG Siok Bian

Being a histo-cytopathologist with speciality training in haematolymphoid and molecular pathology, my research interest is to apply this knowledge and to conduct in-depth study into the pathobiology and molecular mechanisms in haematolymphoid malignancies.


Being a histo-cytopathologist with speciality training in haematolymphoid and molecular pathology, my research interest is to apply this knowledge and to conduct in-depth study into the pathobiology and molecular mechanisms in haematolymphoid malignancies. In the process, I hope the basic research can be translated into human models for diagnostic, prognostic or therapeutic purposes. My training in histopathology, immunohistochemistry and molecular pathology facilitates tissue-based research and validation of novel biomarkers on clinical samples, which is important for translational research.

Principal Associate, Cancer Science Institute, NUS
Associate Professor, Department of Pathology, Yong Loo Lin Medical School, NUS
Senior Consultant, Department of Pathology, National University Hospital

Year(s) Degree (if applicable) Institute
1995 MBBS National University of Singapore
2002 FRCPA Royal College of Pathologists of Australasia
2003 Visiting Fellow National Cancer Institute/National Institute of Health, USA, Bethesda
2013 – Present Principle Associate, Cancer Science Institute of Singapore, NUS
2007 – 2010 Consultant, Department of Pathology, NUS
2005 – 2007 Consultant, Dept of Laboratory (Histopathology), KK Women’s and Children’s Hospital
2004 – 2005 Consultant, Dept of Pathology, Singapore General Hospital
2002 – 2004 Associate Consultant, Dept of Pathology, Singapore General Hospital


EBV-associated T/NK lymphoproliferative disorders are an important group of diseases because they are prevalent in Asia and clinical outcome is generally dismal as there are no reliable prognostic markers and effective therapy is lacking. The pathobiology of EBV-associated T/NK lymphomas is poorly understood and the role of EBV in the oncogenesis is yet to be established. Hence, it is important to conduct in-depth study into the pathogenesis and molecular mechanisms of these tumours.

In the last few years, Dr Ng’s research focus has been on EBV-associated T/NK-cell lymphoproliferative disorders, and in particular, extranodal NK/T cell lymphoma (NKTCL). Using a combinational analytical approach via gene and miRNA expression profiling on paraffin embedded tissue samples, she has uncovered the molecular signatures and important oncogenic pathways in NKTCL, and identified novel biomarkers and potential therapeutic targets. The long term goal is to delineate and validate key biomarkers and oncogenic pathways in NKTCL and identifying molecular subsets of prognostic and clinical importance.

In collaboration with Massachusetts General Hospital, we have conducted a clinical trial of treating NSCLC patients with sensitizing EGFR mutations with Gefitinib and Hydroxychloroquine, to determine if the progression free survival on Gefitinib can be prolonged. The phase II study has now completed accrual, and biomarkers that may predict response and resistance are currently being studied. Our preliminary studies show that circulating free tumor DNA can be detected in the blood of these patients, and serial blood studies of patients on EGFR TKI therapy may provide useful information about clinical response and progression. Bench studies are also focused on elucidating mechanisms of acquired resistance to EGFR TKI in NSCLC.

Selected Publications

1. Ng SB, Tay JL, Lin B, Koh TL, Tan J, Selvarajan V, Liu SC, Bi C, Wang S, Choo SN, Shimizu N, Huang G, Yu Q, Chng WJ. EZH2 overexpression in natural killer /T-cell lymphoma confers growth advantage independently of histone methyltransferase activity. Blood. 2013 Mar 25. [Epub ahead of print]. PMID:23529930

2. Panneerselvam P, Singh LP, Selvarajan V, Chng WJ, Ng SB, Tan NS, Ho B, Chen J, Ding JL. T-cell death following immune activation is mediated by mitochondria-localized SARM. Cell Death Differ. 2013 Mar;20(3):478-89 [Epub ahead of print] PubMed PMID: 23175186.

3. Tan SY, Chuang SS, Tang T, Tan L, Ko YH, Chuah KL, Ng SB, Chng WJ, Gatter K, Loong F, Liu YH, Hosking P, Cheah PL, Teh BT, Tay K, Koh M, Lim ST. Type II EATL (Epitheliotropic Intestinal T-cell Lymphoma): a neoplasm of intra-epithelial T-cells with predominant CD8?? phenotype. Leukemia. 2013 Feb 12. doi: 10.1038/leu.2013.41. [Epub ahead of print] PMID:23399895

4. Croxford JL, Tang ML, Pan MF, Huang CW, Kamran N, Phua CM, Chng WJ, Ng SB, Raulet DH, Gasser S. ATM-dependent spontaneous regression of early E?-myc-induced murine B cell leukemia depends on NK and T cells. Blood. 2013 Jan 24. [Epub ahead of print] PMID:23349395

5. Tse E, Gill H, Loong F, Kim SJ, Ng SB, Tang T, Ko YH, Chng WJ, Lim ST, Kim WS, Kwong YL. Type II enteropathy associated T-cell lymphoma: a retrospective multi-center analysis from the Asia Lymphoma Study Group. Am J Hematol. 2012 Jul;87(7):663-8. Epub 2012 May 28.

6. Ng SB, Yan J, Huang G, Selvarajan V, Tay JL, Lin B, Bi C, Tan J, Kwong YL, Shimizu N, Aozasa K, Chng WJ. Dysregulated microRNAs affect pathways and targets of biological relevance in nasal-type natural killer/T-cell lymphoma. Blood. 2011 Nov 3;118(18):4919-29. Epub 2011 Sep 14.

7. Chng WJ, Huang GF, Chung TH, Ng SB, Gonzalez-Paz N, Troska-Price T, Mulligan G, Chesi M, Bergsagel PL, Fonseca R. Clinical and biological implications of MYC activation: A common difference between MGUS and newly diagnosed multiple myeloma. Leukemia. 2011 Jun;25(6):1026-35

8. Ng SB, Selvarajan V, Huang G, Zhou J, Feldman AL, Law M, Kwong YL, Shimizu N, Kagami Y, Aozasa K, Salto-Tellez M, Chng WJ. Activated Oncogenic Pathways and Therapeutic Targets in Extranodal Nasal-Type NK/T Cell Lymphoma Revealed by Gene Expression Profiling. J Pathol. 2011 Mar;223(4):496-510

9. Ng SB, Khoury JD. Epstein-Barr Virus in Lymphoproliferative Processes: An update for the diagnostic pathologist. Adv Anat Pathol 2009 Jan; 16(1):40-55

10. Ng SB, Lai KW, Murugaya S, Lee KM, Loong SL, Fook-Chong S, Tao M, Sng I. Nasal-type extranodal natural killer/T-cell lymphomas: a clinicopathologic and genotypic study of 42 cases in Singapore. Mod Pathol 2004;17(9):1097-1107